MBX Biosciences, Inc./$MBX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MBX Biosciences, Inc.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
Ticker
$MBX
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
43
ISIN
US55287L1017
Website
MBX Metrics
BasicAdvanced
$344M
-
-$3.93
-
-
Price and volume
Market cap
$344M
52-week high
$14.34
52-week low
$4.81
Average daily volume
227K
Financial strength
Current ratio
23.307
Quick ratio
23.106
Total debt to equity
0.055
Profitability
EBITDA (TTM)
-81.136
Management effectiveness
Return on assets (TTM)
-31.68%
Return on equity (TTM)
-48.22%
Valuation
Price to book
1.46
Price to tangible book (TTM)
1.46
Price to free cash flow (TTM)
-2.857
Free cash flow yield (TTM)
-35.01%
Free cash flow per share (TTM)
-359.87%
Growth
Earnings per share change (TTM)
-88.85%
Bulls say / Bears say
MBX Biosciences completed enrollment in its Phase 2 Avail™ trial of MBX 2109 (Canvuparatide) for hypoparathyroidism, with topline results expected in Q3 2025, potentially leading to significant advancements in treatment options. (MBX Biosciences News Release)
The company reported a strong cash position of $277.1 million as of Q3 2024, projected to sustain operations until mid-2027, providing financial stability for ongoing and future projects. (Nasdaq)
MBX Biosciences raised approximately $187.7 million through its upsized initial public offering in September 2024, enhancing its financial resources for research and development. (Reuters)
MBX Biosciences reported a net loss of $61.9 million for the year ended December 31, 2024, reflecting the high costs associated with its active development phase. (Nasdaq)
The company's lead candidate, MBX 2109, is still in Phase 2 trials, and any delays or unfavorable results could negatively impact investor confidence and stock value. (MBX Biosciences News Release)
MBX Biosciences operates in a highly competitive sector, with established companies like Eli Lilly and Novo Nordisk already marketing effective weight-loss drugs, potentially limiting MBX's market share upon product approval. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
MBX News
AllArticlesVideos
MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity
GlobeNewsWire·5 days ago
MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions
GlobeNewsWire·2 weeks ago
MBX Biosciences to Participate in June Investor Conferences
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MBX Biosciences, Inc. stock?
MBX Biosciences, Inc. (MBX) has a market cap of $344M as of June 21, 2025.
What is the P/E ratio for MBX Biosciences, Inc. stock?
The price to earnings (P/E) ratio for MBX Biosciences, Inc. (MBX) stock is 0 as of June 21, 2025.
Does MBX Biosciences, Inc. stock pay dividends?
No, MBX Biosciences, Inc. (MBX) stock does not pay dividends to its shareholders as of June 21, 2025.
When is the next MBX Biosciences, Inc. dividend payment date?
MBX Biosciences, Inc. (MBX) stock does not pay dividends to its shareholders.
What is the beta indicator for MBX Biosciences, Inc.?
MBX Biosciences, Inc. (MBX) does not currently have a Beta indicator.